FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975650599> ?p ?o ?g. }

• W1975650599 endingPage "S138" @default.
• W1975650599 startingPage "S135" @default.
• W1975650599 abstract "Allergic rhinitis (AR) is part of a systemic disease complex. There is a close relationship between AR and asthma, which has led to the “one airway, one disease” concept. Both conditions share common immunopathology and pathophysiology. In patients with AR, allergen-triggered early and late responses are mediated by a series of inflammatory cells. Within minutes of contact with allergen, IgE-sensitized mast cells degranulate, releasing both preformed and newly synthesized mediators. Immunologic processes in both nasal and bronchial tissue involve TH2 lymphocytes and eosinophils. Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase allergic response. Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13. Neuropeptides also appear to contribute to the pathophysiology of AR symptoms. Both AR and asthma exhibit marked day-night variation in symptom severity. Acknowledging both the chronobiology of AR and circadian rhythm–dependent attributes of antiallergy medications might enhance the beneficial effects of allergy therapies. Allergic rhinitis (AR) is part of a systemic disease complex. There is a close relationship between AR and asthma, which has led to the “one airway, one disease” concept. Both conditions share common immunopathology and pathophysiology. In patients with AR, allergen-triggered early and late responses are mediated by a series of inflammatory cells. Within minutes of contact with allergen, IgE-sensitized mast cells degranulate, releasing both preformed and newly synthesized mediators. Immunologic processes in both nasal and bronchial tissue involve TH2 lymphocytes and eosinophils. Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase allergic response. Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13. Neuropeptides also appear to contribute to the pathophysiology of AR symptoms. Both AR and asthma exhibit marked day-night variation in symptom severity. Acknowledging both the chronobiology of AR and circadian rhythm–dependent attributes of antiallergy medications might enhance the beneficial effects of allergy therapies. Allergic rhinitis (AR) is the most common atopic disease in the United States and is estimated to affect up to 25% of adults and more than 40% of children. Strikingly, close to 80 million individuals experience manifestations of AR, nasal-ocular symptoms, for more than 7 days a year. The associated socioeconomic costs are similarly significant because AR affects school performance, socialization, and work productivity.1Nathan R.A. Meltzer E.O. Selner J.C. Storms W. Prevalence of allergic rhinitis in the United States.J Allergy Clin Immunol. 1997; 99: S808-S814Abstract Full Text PDF Scopus (269) Google Scholar, 2Adams P.F. Hendershot G.E. Marano M.A. Current estimates from the national health interview survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics, Atlanta1999Google Scholar, 3Ma X. Fick R.B. Kaplowitz H.J. Prevalence of allergic rhinoconjunctivitis in the United States: data from the third National Health and Nutrition Examination Survey, 1988-94 (NHANES III).Am J Crit Care Med. 2000; 161 ([abstract]): 325Google Scholar, 4Wright A.L. Holberg C.J. Martinez F.D. Halonen M. Morgan W. Taussig L.M. Epidemiology of physician-diagnosed allergic rhinitis in childhood.Pediatrics. 1994; 94: 895-901PubMed Google ScholarPathophysiology of allergic rhinitisAs with the other atopic disorders such as asthma, eczema, and food allergy, AR is part of a systemic disease complex. Within minutes of exposure to allergen, sensitized mast cells release mediators that result in early symptoms, as well as the recruitment of additional inflammatory cells, causing later symptoms and maintaining the disease process. Even the term “hay fever” connotes the findings that the nasal-ocular symptoms of AR elicited by antigen are also associated with systemic manifestations, the consequence of mediator release.There is a very close relationship between AR and allergic asthma. In fact, the 2 conditions are manifestations of one syndrome in 2 regions of the respiratory tract, leading to a “chronic allergic respiratory syndrome.” As stressed recently, AR and asthma can be considered “one airway, one disease.” It is well recognized that more than 80% of persons with allergic asthma have AR and that AR is a risk factor for the development of asthma. The 2 conditions also share a common immunopathology and pathophysiology.5Bousquet J. Van Cauwenberge P. Khaltaev N. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol. 2001; 108: S147-S334Abstract Full Text Full Text PDF PubMed Scopus (2156) Google Scholar, 6Simons F.E. Allergic rhinobronchitis: the asthma-allergic rhinitis link.J Allergy Clin Immunol. 1999; 104: 534-540Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar, 7Togias A. Rhinitis and asthma: evidence for respiratory system integration.J Allergy Clin Immunol. 2003; 111: 1171-1184Abstract Full Text Full Text PDF PubMed Scopus (371) Google Scholar As outlined in Table I, they share similar immunologic processes, the findings in nasal and bronchial tissue are similar, and TH2 lymphocytes, mast cells, and eosinophils are involved in both conditions. In both AR and asthma, early- and late-phase responses can be elicited, and hyperresponsive states, sensorineural in the nasal passages and in the airways in response to allergen challenge, can also be demonstrated.Table IImmunopathology and pathophysiology common to AR and asthmaSimilar immunologic processesSimilar findings in nasal and bronchial tissueEosinophils, mast cellsTH2 lymphocytesEarly- and late-phase responsesHyperresponsiveness: sensorineural in nasal passages and airways in response to allergen challenge Open table in a new tab Within minutes of contact with allergen, IgE-sensitized mast cells degranulate and release a series of preformed and newly synthesized mediators. Many of these mediators lead to the characteristic symptoms of AR, including sneezing, itchiness, rhinorrhea, and congestion. These early-phase responses have been attributed to the immediate release of cysteinyl leukotrienes, prostaglandins, histamine, and cytokines. Histamine has been shown to elicit virtually all of the early-phase responses, primarily through binding to the H1 receptor.8White M.V. Kaliner M.A. Mediators of allergic rhinitis.J Allergy Clin Immunol. 1992; 90: 699-704Abstract Full Text PDF PubMed Scopus (91) Google Scholar, 9Togias A. Unique mechanistic features of allergic rhinitis.J Allergy Clin Immunol. 2000; 105: S599-S604Abstract Full Text Full Text PDF PubMed Scopus (120) Google ScholarIn the second, or late, phase of the AR response, congestion becomes more prominent. As a result of cytokine or mediator release, the nasal mucosa becomes infiltrated with inflammatory cells, basophils, eosinophils, neutrophils, mast cells, and mononuclear cells, further sustaining the nasal mucosal inflammatory reaction.5Bousquet J. Van Cauwenberge P. Khaltaev N. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol. 2001; 108: S147-S334Abstract Full Text Full Text PDF PubMed Scopus (2156) Google Scholar, 10Ledford D.K. Lockey R.F. Allergic rhinitis: Understanding the process (a major contributor to health problems and on the rise).J Respir Dis. 1998; 19: 576-584Google Scholar, 11Bascom R. Pipkorn U. Lichtenstein L.M. Naclerio R.M. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment.Am Rev Respir Dis. 1988; 138: 406-412Crossref PubMed Scopus (261) Google Scholar Histamine acting through H1 receptors, as well as through H2, H3, and H4 receptors, might increase expression of adhesion molecules and increase production of a number of proinflammatory cytokines.12Gelfand E.W. Role of histamine in the pathophysiology of asthma: Immunomodulatory and anti-inflammatory activities of H1-receptor antagonists.Am J Med. 2002; 113: S2-S7Abstract Full Text Full Text PDF PubMed Google ScholarOver the course of an allergy season, there might be a 10-fold increase in the numbers of nasal epithelial and submucosal mast cells.13Viegas M. Gomez E. Brooks J. Gatland D. Davies R.J. Effect of the pollen season on nasal mast cells.BMJ. 1987; 294: 414Crossref PubMed Scopus (52) Google Scholar In fact, the number might correlate very well with pollen counts. These mast cells might not only play important roles during the initial AR response but also might be key to sustaining this response into a more chronic phase. One interesting possibility is that mast cell–derived lipid mediators and histamine might be important in the recruitment of TH2 lymphocytes to target organs.Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase response. The influx of eosinophils correlates with the development and progression of symptoms.14Harlin S.L. Ansel D.G. Lane S.R. Myers J. Kephart G.M. Gleich G.J. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil.J Allergy Clin Immunol. 1988; 81: 867-875Abstract Full Text PDF PubMed Scopus (293) Google Scholar, 15Juliusson S. Pipkorn U. Karlsson G. Enerback L. Mast cells and eosinophils in the allergic mucosa response to allergen challenge: changes in distribution and signs of activation in relation to symptoms.J Allergy Clin Immunol. 1992; 90: 898-909Abstract Full Text PDF PubMed Scopus (88) Google Scholar, 16Pipkorn U. Karlsson G. Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure.J Allergy Clin Immunol. 1988; 82: 1046-1054Abstract Full Text PDF PubMed Scopus (134) Google Scholar Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13.17Bjornsdottir U.S. Cypcar D.M. Asthma: an inflammatory mediator soup.Allergy. 1999; 54: 55-61Crossref PubMed Google Scholar The cysteinyl leukotrienes have many activities that are linked to the symptomatology of AR, as well as the recruitment and activation of eosinophils (Table II).18Creticos P.S. Peters S.P. Adkinson Jr., N.F. Naclerio R.M. Hayes E.C. Norman P.S. et al.Peptide leukotriene release after antigen challenge in patients sensitive to ragweed.N Engl J Med. 1984; 310: 1626-1630Crossref PubMed Scopus (305) Google Scholar, 19Wang D. Clement P. Smitz J. Derde M.P. Concentrations of chemical mediators in nasal secretions of patients with hay fever during natural allergen exposure.Acta Otolaryngol. 1994; 114: 552-555Crossref PubMed Scopus (28) Google Scholar, 20Wang D. Clement P. Smitz J. De Waele M. Derde M.P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure.Int Arch Allergy Immunol. 1995; 106: 278-285Crossref PubMed Scopus (104) Google Scholar, 21Bisgaard H. Olsson P. Bende M. Effect of leukotriene D4 on nasal mucosa blood flow, nasal airway resistance and nasal secretion in humans.Clin Allergy. 1986; 16: 289-297Crossref PubMed Scopus (176) Google Scholar, 22Howarth P.H. Mediators of nasal blockage in allergic rhinitis.Allergy. 1997; 52: 12-18Crossref PubMed Scopus (76) Google Scholar, 23Okuda M. Watase T. Mezawa A. Liu C.M. The role of leukotriene D4 in allergic rhinitis.Ann Allergy Asthma Immunol. 1988; 60: 537-540Google Scholar, 24Miadonna A. Tedeschi A. Leggieri E. Lorini M. Folco G. Sala A. et al.Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis.Am Rev Respir Dis. 1987; 136: 357-362Crossref PubMed Scopus (115) Google Scholar, 25Spada C.S. Krauss A.H. Nieves A.L. Woodward D.F. Effects of leukotrienes B4 (LTB4) and D4 (LTD4) on motility of isolated normodense human eosinophils and neutrophils.Adv Exp Med Biol. 1997; 400B: 699-706PubMed Google Scholar, 26Fregonese L. Silvestri M. Sabatini F. Rossi G.A. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism.Clin Exp Allergy. 2002; 32: 745-750Crossref PubMed Scopus (84) Google ScholarTable IICysteinyl leukotrienes in ARIncreased levels in nasal fluid after allergen challengeLevels correlate with eosinophil cationic protein levelsContribute to both early and late phase Nasal congestion Sneezing, rhinorrheaChemoattractant for eosinophilsPromote eosinophil adhesionDecrease eosinophil apoptosisFacilitate growth of eosinophil precursors (with GM-CSF, IL-5) Open table in a new tab Our understanding of the role of neuropeptides in AR is limited and is an area of growing interest. The nasal mucosa is highly innervated, and neuropeptides are involved in the pathophysiology and contribute to many of the symptoms of AR (Table III, Table IV).Table IIIAction of neuropeptides in ARVasoconstriction and decreases in nasal airway resistance result from sympathetic nerve stimulation.Parasympathetic nerve stimulation promotes secretion from nasal airway glands and nasal congestion.Nasal mucosa contains nerves of the nonadrenergic, noncholinergic system. Open table in a new tab Table IVRole of neuropeptides in ARSubstance P, neurokinin A, neurokinin K, calcitonin gene-related peptideVasodilationMucus secretionPlasma extravasationNeurogenic inflammationMast cell–nerve interactions Open table in a new tab The nasal and bronchial mucosa are very similar, with columnar ciliated cells positioned over a basement membrane. The inflammatory infiltrate in asthma and AR is also very similar, as are the triggers to a large extent.27Bousquet J. Jeffery P.K. Busse W.W. Johnson M. Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling.Am J Respir Crit Care Med. 2000; 161: 1720-1745Crossref PubMed Scopus (1544) Google Scholar, 28Durham S.R. Ying S. Varney V.A. Jacobson M.R. Sudderick R.M. Mackay I.S. et al.Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia.J Immunol. 1992; 148: 2390-2394PubMed Google Scholar, 29Kay A.B. Allergy and allergic diseases. First of two parts.N Engl J Med. 2001; 344: 30-37Crossref PubMed Scopus (901) Google Scholar, 30Busse W.W. Lemanske Jr., R.F. Asthma.N Engl J Med. 2001; 344: 350-362Crossref PubMed Scopus (1698) Google Scholar There are also important differences (Table V). The embryonic development of the upper and lower airways differs, suggesting that the genes governing repair or remodeling are different.31Larsen W. Development of the head and neck.in: Human embryology. Churchill Livingstone, New York2001: 351-378Google Scholar Smooth muscle is only present in the bronchi. In the nose there is a large supply of subepithelial capillaries, arterial systems, and venous cavernous sinusoids.Table VDifferences between the upper and lower airwaysNose (ectodermal) and bronchial (endodermal) airways have a different embryologic origin.Genes governing repair-remodeling might be different.Smooth muscle is only present in the bronchi.Nose contains a large supply of subepithelial capillaries, arterial systems, and venous cavernous sinusoids. Open table in a new tab Together, these differences are most obvious when remodeling in the upper and lower respiratory tract is considered (Table VI). Remodeling is much more prominent in the lower airways, whereas the nasal mucosa has a much higher capacity for epithelial regeneration and protection.32Chakir J. Laviolette M. Turcotte H. Boutet M. Boulet L.P. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure.J Allergy Clin Immunol. 2000; 106: 904-910Abstract Full Text Full Text PDF PubMed Scopus (84) Google ScholarTable VIRemodeling differs in asthma and ARMagnitude of inflammatory response might differ.Epithelial disruption and desquamation is a feature of the bronchial epithelium in asthma but is less marked in the nasal epithelium with rhinitis.Thickness of the reticular basement membrane is greater in bronchial mucosa than in nasal mucosa. Open table in a new tab Chronobiology of allergic rhinitisWithin the context of homeostasis, biologic functions are not consistent over time, especially during different parts of the day-night cycle. Chronobiology is the science studying biologic rhythms. Circadian rhythms are critically important in medicine. Whether endogenous or exogenous, the activity of biologically important molecules is dependent on circadian rhythmic phenomena that can affect pharmacokinetics and pharmacodynamics. Many diseases are affected by circadian time structure, including asthma and AR. For asthma, peak flows are best around 4 PM and worst at 4 AM. The worsening of lung function in the early morning hours is associated with increased inflammatory cell infiltration of the airways.33Martin R.J. Nocturnal asthma: mechanism and treatment. Futura Publishing Co, Mt Kisco (NY)1993Google ScholarThere is also a striking day-night pattern in AR. Patients with seasonal and perennial AR complain of disturbed sleep at night, as well as symptoms on awakening in the morning. In fact, the earliest description of the chronobiology of AR was by Trousseau in 1865, who described the prominent morning manifestations and intensity of nasal symptoms.34Trousseau A. Clinique medicale de L'Hotel Dieu Paris. Vol 2. Bailliere, Paris1865Google Scholar Since then, many studies have examined day-night variation and intensity of AR. Generally, all show that symptom severity peaks at approximately 6 AM.35Smolensky M.H. Reinberg A. Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications.J Allergy Clin Immunol. 1995; 95: 1087-1096Abstract Full Text Full Text PDF Scopus (56) Google Scholar, 36Binder E. Holopainen E. Malmberg H. Salo O. Anamnestic data in allergic rhinitis.Allergy. 1973; 37: 389-396Crossref Scopus (29) Google Scholar, 37Reinberg A. Gervais P. Levi F. Smolensky M. Del Cerro L. Ugolini C. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods.J Allergy Clin Immunol. 1988; 81: 51-62Abstract Full Text PDF PubMed Scopus (90) Google ScholarThis circadian rhythm for symptoms of AR is intertwined with the pharmacokinetics and dynamics of many medications, which are similarly circadian rhythm dependent. The need for medication might not be consistent throughout the 24-hour cycle. Thus chronotherapy of AR with H1 receptor antagonists might be an important consideration. When examined, these mediations were least effective when most of or all of the daily dose was taken in the morning at breakfast. Evening administration was especially effective, considering the usual peaking of symptoms at 6 AM.38Reinberg A. Chronopharmacology of H1-antihistamines.in: Lemmer B.J. Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York1989: 115-135Google Scholar, 39Reinberg A. Gervais P. Ugolini C. Del Cerro L. Ricakova-Rocher A. Nicolai A. A multicentric chronotherapeutic study of mequitazine in allergic rhinitis.Annu Rev Chronopharmacol. 1985; 3: 441-444Google ScholarConclusionsAR, like other atopic diseases, is the result of allergen-triggered early and late or chronic responses mediated by a series of inflammatory cells and mediators. Although the nasal mucosa is derived from a different embryologic origin, much of the immunopathology is shared between the upper and lower respiratory tracts. Similar to asthma, AR exhibits a marked day-night variation, which currently is often in conflict with administration of, for example, antihistamines in a single dose at breakfast. Failure to acknowledge both the chronobiology of the disease and the circadian rhythm–dependent attributes of the medications will clearly compromise or limit the beneficial effects of many of these therapies. Allergic rhinitis (AR) is the most common atopic disease in the United States and is estimated to affect up to 25% of adults and more than 40% of children. Strikingly, close to 80 million individuals experience manifestations of AR, nasal-ocular symptoms, for more than 7 days a year. The associated socioeconomic costs are similarly significant because AR affects school performance, socialization, and work productivity.1Nathan R.A. Meltzer E.O. Selner J.C. Storms W. Prevalence of allergic rhinitis in the United States.J Allergy Clin Immunol. 1997; 99: S808-S814Abstract Full Text PDF Scopus (269) Google Scholar, 2Adams P.F. Hendershot G.E. Marano M.A. Current estimates from the national health interview survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics, Atlanta1999Google Scholar, 3Ma X. Fick R.B. Kaplowitz H.J. Prevalence of allergic rhinoconjunctivitis in the United States: data from the third National Health and Nutrition Examination Survey, 1988-94 (NHANES III).Am J Crit Care Med. 2000; 161 ([abstract]): 325Google Scholar, 4Wright A.L. Holberg C.J. Martinez F.D. Halonen M. Morgan W. Taussig L.M. Epidemiology of physician-diagnosed allergic rhinitis in childhood.Pediatrics. 1994; 94: 895-901PubMed Google Scholar Pathophysiology of allergic rhinitisAs with the other atopic disorders such as asthma, eczema, and food allergy, AR is part of a systemic disease complex. Within minutes of exposure to allergen, sensitized mast cells release mediators that result in early symptoms, as well as the recruitment of additional inflammatory cells, causing later symptoms and maintaining the disease process. Even the term “hay fever” connotes the findings that the nasal-ocular symptoms of AR elicited by antigen are also associated with systemic manifestations, the consequence of mediator release.There is a very close relationship between AR and allergic asthma. In fact, the 2 conditions are manifestations of one syndrome in 2 regions of the respiratory tract, leading to a “chronic allergic respiratory syndrome.” As stressed recently, AR and asthma can be considered “one airway, one disease.” It is well recognized that more than 80% of persons with allergic asthma have AR and that AR is a risk factor for the development of asthma. The 2 conditions also share a common immunopathology and pathophysiology.5Bousquet J. Van Cauwenberge P. Khaltaev N. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol. 2001; 108: S147-S334Abstract Full Text Full Text PDF PubMed Scopus (2156) Google Scholar, 6Simons F.E. Allergic rhinobronchitis: the asthma-allergic rhinitis link.J Allergy Clin Immunol. 1999; 104: 534-540Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar, 7Togias A. Rhinitis and asthma: evidence for respiratory system integration.J Allergy Clin Immunol. 2003; 111: 1171-1184Abstract Full Text Full Text PDF PubMed Scopus (371) Google Scholar As outlined in Table I, they share similar immunologic processes, the findings in nasal and bronchial tissue are similar, and TH2 lymphocytes, mast cells, and eosinophils are involved in both conditions. In both AR and asthma, early- and late-phase responses can be elicited, and hyperresponsive states, sensorineural in the nasal passages and in the airways in response to allergen challenge, can also be demonstrated.Table IImmunopathology and pathophysiology common to AR and asthmaSimilar immunologic processesSimilar findings in nasal and bronchial tissueEosinophils, mast cellsTH2 lymphocytesEarly- and late-phase responsesHyperresponsiveness: sensorineural in nasal passages and airways in response to allergen challenge Open table in a new tab Within minutes of contact with allergen, IgE-sensitized mast cells degranulate and release a series of preformed and newly synthesized mediators. Many of these mediators lead to the characteristic symptoms of AR, including sneezing, itchiness, rhinorrhea, and congestion. These early-phase responses have been attributed to the immediate release of cysteinyl leukotrienes, prostaglandins, histamine, and cytokines. Histamine has been shown to elicit virtually all of the early-phase responses, primarily through binding to the H1 receptor.8White M.V. Kaliner M.A. Mediators of allergic rhinitis.J Allergy Clin Immunol. 1992; 90: 699-704Abstract Full Text PDF PubMed Scopus (91) Google Scholar, 9Togias A. Unique mechanistic features of allergic rhinitis.J Allergy Clin Immunol. 2000; 105: S599-S604Abstract Full Text Full Text PDF PubMed Scopus (120) Google ScholarIn the second, or late, phase of the AR response, congestion becomes more prominent. As a result of cytokine or mediator release, the nasal mucosa becomes infiltrated with inflammatory cells, basophils, eosinophils, neutrophils, mast cells, and mononuclear cells, further sustaining the nasal mucosal inflammatory reaction.5Bousquet J. Van Cauwenberge P. Khaltaev N. Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol. 2001; 108: S147-S334Abstract Full Text Full Text PDF PubMed Scopus (2156) Google Scholar, 10Ledford D.K. Lockey R.F. Allergic rhinitis: Understanding the process (a major contributor to health problems and on the rise).J Respir Dis. 1998; 19: 576-584Google Scholar, 11Bascom R. Pipkorn U. Lichtenstein L.M. Naclerio R.M. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment.Am Rev Respir Dis. 1988; 138: 406-412Crossref PubMed Scopus (261) Google Scholar Histamine acting through H1 receptors, as well as through H2, H3, and H4 receptors, might increase expression of adhesion molecules and increase production of a number of proinflammatory cytokines.12Gelfand E.W. Role of histamine in the pathophysiology of asthma: Immunomodulatory and anti-inflammatory activities of H1-receptor antagonists.Am J Med. 2002; 113: S2-S7Abstract Full Text Full Text PDF PubMed Google ScholarOver the course of an allergy season, there might be a 10-fold increase in the numbers of nasal epithelial and submucosal mast cells.13Viegas M. Gomez E. Brooks J. Gatland D. Davies R.J. Effect of the pollen season on nasal mast cells.BMJ. 1987; 294: 414Crossref PubMed Scopus (52) Google Scholar In fact, the number might correlate very well with pollen counts. These mast cells might not only play important roles during the initial AR response but also might be key to sustaining this response into a more chronic phase. One interesting possibility is that mast cell–derived lipid mediators and histamine might be important in the recruitment of TH2 lymphocytes to target organs.Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase response. The influx of eosinophils correlates with the development and progression of symptoms.14Harlin S.L. Ansel D.G. Lane S.R. Myers J. Kephart G.M. Gleich G.J. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil.J Allergy Clin Immunol. 1988; 81: 867-875Abstract Full Text PDF PubMed Scopus (293) Google Scholar, 15Juliusson S. Pipkorn U. Karlsson G. Enerback L. Mast cells and eosinophils in the allergic mucosa response to allergen challenge: changes in distribution and signs of activation in relation to symptoms.J Allergy Clin Immunol. 1992; 90: 898-909Abstract Full Text PDF PubMed Scopus (88) Google Scholar, 16Pipkorn U. Karlsson G. Enerback L. The cellular response of the human allergic mucosa to natural allergen exposure.J Allergy Clin Immunol. 1988; 82: 1046-1054Abstract Full Text PDF PubMed Scopus (134) Google Scholar Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13.17Bjornsdottir U.S. Cypcar D.M. Asthma: an inflammatory mediator soup.Allergy. 1999; 54: 55-61Crossref PubMed Google Scholar The cysteinyl leukotrienes have many activities that are linked to the symptomatology of AR, as well as the recruitment and activation of eosinophils (Table II).18Creticos P.S. Peters S.P. Adkinson Jr., N.F. Naclerio R.M. Hayes E.C. Norman P.S. et al.Peptide leukotriene release after antigen challenge in patients sensitive to ragweed.N Engl J Med. 1984; 310: 1626-1630Crossref PubMed Scopus (305) Google Scholar, 19Wang D. Clement P. Smitz J. Derde M.P. Concentrations of chemical mediators in nasal secretions of patients with hay fever during natural allergen exposure.Acta Otolaryngol. 1994; 114: 552-555Crossref PubMed Scopus (28) Google Scholar, 20Wang D. Clement P. Smitz J. De Waele M. Derde M.P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure.Int Arch Allergy Immunol. 1995; 106: 278-285Crossref PubMed Scopus (104) Google Scholar, 21Bisgaard H. Olsson P. Bende M. Effect of leukotriene D4 on nasal mucosa blood flow," @default.
• W1975650599 created "2016-06-24" @default.
• W1975650599 creator A5023960478 @default.
• W1975650599 date "2004-11-01" @default.
• W1975650599 modified "2023-10-15" @default.
• W1975650599 title "Inflammatory mediators in allergic rhinitis" @default.
• W1975650599 cites W1497022815 @default.
• W1975650599 cites W1793140192 @default.
• W1975650599 cites W1932009057 @default.
• W1975650599 cites W195308010 @default.
• W1975650599 cites W1967798864 @default.
• W1975650599 cites W1971393493 @default.
• W1975650599 cites W1973222101 @default.
• W1975650599 cites W1978837864 @default.
• W1975650599 cites W1979845026 @default.
• W1975650599 cites W1992158509 @default.
• W1975650599 cites W2004818687 @default.
• W1975650599 cites W2011691559 @default.
• W1975650599 cites W2016752440 @default.
• W1975650599 cites W2027242741 @default.
• W1975650599 cites W2030407233 @default.
• W1975650599 cites W2030990965 @default.
• W1975650599 cites W2039239585 @default.
• W1975650599 cites W2058644368 @default.
• W1975650599 cites W2063322970 @default.
• W1975650599 cites W2077221957 @default.
• W1975650599 cites W2080502516 @default.
• W1975650599 cites W2083610245 @default.
• W1975650599 cites W2096210343 @default.
• W1975650599 cites W2106358194 @default.
• W1975650599 cites W2119539558 @default.
• W1975650599 cites W2121464855 @default.
• W1975650599 cites W2130614990 @default.
• W1975650599 cites W2136870618 @default.
• W1975650599 cites W2157987486 @default.
• W1975650599 cites W2327878210 @default.
• W1975650599 cites W2404956970 @default.
• W1975650599 cites W638290765 @default.
• W1975650599 cites W1528208366 @default.
• W1975650599 doi "https://doi.org/10.1016/j.jaci.2004.08.043" @default.
• W1975650599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15536444" @default.
• W1975650599 hasPublicationYear "2004" @default.
• W1975650599 type Work @default.
• W1975650599 sameAs 1975650599 @default.
• W1975650599 citedByCount "176" @default.
• W1975650599 countsByYear W19756505992012 @default.
• W1975650599 countsByYear W19756505992013 @default.
• W1975650599 countsByYear W19756505992014 @default.
• W1975650599 countsByYear W19756505992015 @default.
• W1975650599 countsByYear W19756505992016 @default.
• W1975650599 countsByYear W19756505992017 @default.
• W1975650599 countsByYear W19756505992018 @default.
• W1975650599 countsByYear W19756505992019 @default.
• W1975650599 countsByYear W19756505992020 @default.
• W1975650599 countsByYear W19756505992021 @default.
• W1975650599 countsByYear W19756505992022 @default.
• W1975650599 countsByYear W19756505992023 @default.
• W1975650599 crossrefType "journal-article" @default.
• W1975650599 hasAuthorship W1975650599A5023960478 @default.
• W1975650599 hasBestOaLocation W19756505991 @default.
• W1975650599 hasConcept C203014093 @default.
• W1975650599 hasConcept C207480886 @default.
• W1975650599 hasConcept C2779675166 @default.
• W1975650599 hasConcept C71924100 @default.
• W1975650599 hasConceptScore W1975650599C203014093 @default.
• W1975650599 hasConceptScore W1975650599C207480886 @default.
• W1975650599 hasConceptScore W1975650599C2779675166 @default.
• W1975650599 hasConceptScore W1975650599C71924100 @default.
• W1975650599 hasLocation W19756505991 @default.
• W1975650599 hasLocation W19756505992 @default.
• W1975650599 hasOpenAccess W1975650599 @default.
• W1975650599 hasPrimaryLocation W19756505991 @default.
• W1975650599 hasRelatedWork W1077212614 @default.
• W1975650599 hasRelatedWork W1967978164 @default.
• W1975650599 hasRelatedWork W1993464074 @default.
• W1975650599 hasRelatedWork W2043111956 @default.
• W1975650599 hasRelatedWork W2086810127 @default.
• W1975650599 hasRelatedWork W2095760150 @default.
• W1975650599 hasRelatedWork W2418156272 @default.
• W1975650599 hasRelatedWork W3153640002 @default.
• W1975650599 hasRelatedWork W4239207266 @default.
• W1975650599 hasRelatedWork W2501188369 @default.
• W1975650599 hasVolume "114" @default.
• W1975650599 isParatext "false" @default.
• W1975650599 isRetracted "false" @default.
• W1975650599 magId "1975650599" @default.
• W1975650599 workType "article" @default.